Influence of Triflusal on Cognitive Functions in Healthy Subjects
NCT ID: NCT02321852
Last Updated: 2015-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
40 participants
INTERVENTIONAL
2015-01-31
2015-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease
NCT01009255
Influence of Losartan and Diphenhydramine on Emotional and Cognitive Functions in Healthy Human Subjects
NCT01321021
Influence of Cincalcet on Cognitive Functions in Healthy Human Subjects
NCT01599962
Modulation of Attention in Event Related Potential (ERPs) as a Marker of Early Cognitive Decline by Ginkgo Biloba
NCT04121728
A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
NCT03538522
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary study outcomes are:
Performance in picturial and verbal memory tasks.
Main secondary outcomes are: Performance in working memory and cognitive tasks and influence on mood, depression and anxiety and motivation.
Once daily oral administration of placebo mannitol for 7 days in a cross-over trial with a washout period of at least 14 days between the two periods. Each participant will take triflusal as well as placebo
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Verum/Placebo
This group will start with triflusal and after washout will receive placebo
Triflusal
Once daily oral administration of 600 mg triflusal Disgren® for 7 days.
Placebo
Once daily oral administration of placebo mannitol for 7 days
Placebo/Verum
This group will start with placebo and will receive triflusal after washout.
Triflusal
Once daily oral administration of 600 mg triflusal Disgren® for 7 days.
Placebo
Once daily oral administration of placebo mannitol for 7 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Triflusal
Once daily oral administration of 600 mg triflusal Disgren® for 7 days.
Placebo
Once daily oral administration of placebo mannitol for 7 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female
* Normotensive
* BMI between 20 and 27 kg/m2
* Aged between 18 and 40 years
* Native or fluent German-speaking
* Caucasian
* Female practicing safe contraception
Exclusion Criteria
* Any contraindication against aspirin or other NSAIDS
* History of coagulation disease
* History of gastrointestinal disease
* Pathological ECG
* Pregnancy, breast-feeding
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Prof. Dominique de Quervain, MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dominique de Quervain, MD
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dominique De Quervain, MD
Role: PRINCIPAL_INVESTIGATOR
Division of Cognitive Neuroscience University of Basel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Basel, Division of Cognitive Neuroscience
Basel, Basel, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014DR2154
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.